Sundial Growers Inc. and Vir Pharma Holdings Pty Ltd. announced a three-year agreement where Sundial will supply medical cannabis oil for Vir Pharma's unique oral formulation for chronic pain that will be used for sales and clinical studies in Australia. Vir Pharma's clinical studies contribute to the development of a proprietary cannabis-based prescription drug for Therapeutic Goods Administration (TGA) approval called Virabis. The drug is intended to treat chronic pain, providing patients with an alternative to current opioid-based treatments. Pursuant to the Agreement, Sundial will work with Vir Pharma to develop a cannabis oil blend focused on chronic pain, which will be marketed under Vir Pharma's brand name, Virabis. The relationship between Sundial and Vir Pharma will enable shared learnings and capabilities, allowing both parties to leverage each other's expertise and opening the door to developing innovative medical cannabis therapies moving forward. Sundial expects to export the first shipment of cannabis oil to Vir Pharma before the end of April 2020.